Early access to antiretroviral therapy versus standard of care among HIV‐positive participants in Eswatini in the public health sector: the MaxART stepped‐wedge randomized controlled trial
Open Access
- 19 September 2020
- journal article
- research article
- Published by Wiley in Journal of the International AIDS Society
- Vol. 23 (9)
Abstract
Introduction: The WHO recommends antiretroviral treatment (ART) for all HIV‐positive patients regardless of CD4 count or disease stage, referred to as “Early Access to ART for All” (EAAA). The health systems effects of EAAA implementation are unknown. This trial was implemented in a government‐managed public health system with the aim to examine the “real world” impact of EAAA on care retention and viral suppression.Methods: In this stepped‐wedge randomized controlled trial, 14 public sector health facilities in Eswatini were paired and randomly assigned to stepwise transition from standard of care (SoC) to EAAA. ART‐naïve participants ≥18 years who were not pregnant or breastfeeding were eligible for enrolment. We used Cox proportional hazard models with censoring at clinic transition to estimate the effects of EAAA on retention in care and retention and viral suppression combined.Results: Between September 2014 and August 2017, 3405 participants were enrolled. In SoC and EAAA respectively, 12‐month HIV care retention rates were 80% (95% CI: 77 to 83) and 86% (95% CI: 83 to 88). The 12‐month combined retention and viral suppression endpoint rates were 44% (95% CI: 40 to 48) under SoC compared to 80% (95% CI: 77 to 83) under EAAA. EAAA increased both retention (HR: 1·60, 95% CI: 1·15 to 2·21,p = 0.005) and retention and viral suppression combined (HR: 4.88, 95% CI: 2.96 to 8.05,p < 0.001). We also identified significant gaps in current health systems ability to provide viral load (VL) monitoring with 80% participants in SoC and 66% in EAAA having a missing VL at last contact.Conclusions: The observed improvement in retention in care and on the combined retention and viral suppression provides an important co‐benefit of EAAA to HIV‐positive adults themselves, at least in the short term. Our results from this “real world” health systems trial strongly support EAAA for Eswatini and countries with similar HIV epidemics and health systems. VL monitoring needs to be scaled up for appropriate care management.Keywords
Funding Information
- National Institute of Child Health and Human Development (R01‐HD084233)
- Alexander von Humboldt-Stiftung
- National Institute of Allergy and Infectious Diseases (R01‐AI112339, R01‐AI124389)
- European Commission
- Wellcome Trust
- Fogarty International Center (D43‐TW009775)
This publication has 31 references indexed in Scilit:
- Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trialThe Lancet Infectious Diseases, 2014
- Interventions to improve adherence to antiretroviral therapyAIDS, 2014
- Interventions to improve the performance of HIV health systems for treatment-as-prevention in sub-Saharan AfricaCurrent Opinion in HIV and AIDS, 2012
- Interventions to increase antiretroviral adherence in sub-Saharan Africa: a systematic review of evaluation studiesThe Lancet Infectious Diseases, 2011
- Retention in HIV Care for Individuals Not Yet Eligible for Antiretroviral Therapy: Rural KwaZulu-Natal, South AfricaJAIDS Journal of Acquired Immune Deficiency Syndromes, 2011
- Retention in Care: A Challenge to Survival with HIV InfectionClinical Infectious Diseases, 2007
- Comparing smoothing techniques in Cox models for exposure–response relationshipsStatistics in Medicine, 2007
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999
- No Adjustments Are Needed for Multiple ComparisonsEpidemiology, 1990
- The Robust Inference for the Cox Proportional Hazards ModelJournal of the American Statistical Association, 1989